Q2PHARMA - Leading Team
Jacob BenArie, MBA, B.Sc, Co-founder and CEO
15+ years of experience as a CEO and entrepreneur in life science start–up companies. Prior to establishing Q2Pharma, Jacob served as the CEO of Orgenesis (OTCBB:ORGS) a cell therapy company aimed to cure diabetes by transdifferentiating liver cells into autologous insulin producing cells. Jacob established Orgenesis activities in Israel, USA and Belgium. Previously served as a co-founder and CEO of Beta-Stim Ltd. a privately held Israeli company backed up by Boston Scientific, aimed to develop a treatment for obese type 2 diabetics. Jacob also co-fuonded Slender Medical Ltd, an ultrasound based product for removal of cellulitis and body contouring. Jacob is also a co-founder of Jaz Medical Ltd, a private held boutique investment house dedicated to pre seed medical devices and also co-founded the MDDMI conference in Israel.
Menachem Shoham, PhD, Co-founder and CSO
Associate Professor, Case Western Reserve University, Cleveland, OH, USA.
- Shoham received his PhD from the Weizmann Institute in 1979, postdoc 1978-1981 at Yale University, Junior & Senior Scientist 1981-1988 at Weizmann Institute , Research Scientist 1988-89 at DuPont
- Shoham served on the NIAID Biodefense and Emerging Infectious Disease Special Emphasis Panel ZAI1, RWM-M (C1), 2013.
Yaron Shoham MD, Co-founder and CMO
Senior Plastic and Reconstructive Surgeon at Soroka University Medical Center, Israel, and Lecturer in Plastic and Reconstructive Surgery at the Faculty of Health Sciences, Ben-Gurion University. Main fields of expertise are wounds, burns and reconstruction. Yaron serves as a member of the International Society of Burn Injury Disaster Management committee, and as an editorial board member and reviewer for several journals.
Yair Alerganti, B.Sc, Co-founder and Chief RA
17 years of experience in clinical studies in field of medical devices and pharmaceuticals. Prior to Q2Pharma, Yair established TRS Ltd (a CRO), served as VP Clinical development at HealOr Ltd and managed the Israeli Clinical Studies at Novartis in oncology, hematology and endocrinology areas. Prior to Novartis he headed the clinical operation at NanoPass and lead the product through 510K approval and CE Mark. Yair holds a bachelor degree in Biology and studies of Pharmacoepidemiology, both from Ben-Gurion University at the Negev.